Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has received approval from the US...
Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC
China-based Jacobio Pharma (HKG: 1167) announced that it has received marketing approval from the National...
AstraZeneca Shuts Down Neuroscience Research Group to Focus on Core Areas
AstraZeneca (AZ; NASDAQ: AZN) confirmed the closure of its neuroscience research group during its 2025...
Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing...
Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg/mL intravitreal ocular...
Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to acquire a 64.81%...
Chongqing Genrix Bio’s GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) recently announced that its New Drug...
Medtronic Plans to Spin Off Diabetes Business into Publicly Traded Entity
Medtronic plc (NYSE: MDT), the US-headquartered medical technology company, has unveiled plans to spin off...
Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation
German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for...
InnoCare Pharma’s Minjuvi Gains NMPA Approval for DLBCL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the National Medical Products Administration (NMPA)...
Uni-Bio Science’s Generic Diquas Accepted for NMPA Review
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...
MicusRx’s Contezolid Sodium NDA Accepted for Review by NMPA
China-based Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) announced that a New Drug Application (NDA)...
Sanofi to Acquire Vigil Neuroscience to Boost Neurology Pipeline
French pharmaceutical giant Sanofi (NASDAQ: SNY) is set to acquire US-based Vigil Neuroscience, Inc., a...
Eli Lilly’s Kisunla Approved in Australia for Alzheimer’s Treatment
The Australian Therapeutic Goods Administration (TGA) this week approved Eli Lilly and Company’s (NYSE: LLY)...
Shanghai INT Medical Instruments to Acquire Majority Stake in Endonom Medical
China-based Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) is set to jointly acquire a...
Medtronic Reports Q4 and FY2025 Results with Revenue Growth Across Key Segments
US-Irish firm Medtronic (NYSE: MDT) released financial results for its fourth quarter (Q4) and fiscal...
Genentech and Orionis Enter Second Collaboration on Small-Molecule Oncology Drugs
Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY), this week entered...
Kexing Biopharm’s GB18 Receives FDA Approval for Tumor Cachexia Clinical Trial
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...
Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment
Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...
Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...